GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » Return-on-Tangible-Equity

Goldenwell Biotech (Goldenwell Biotech) Return-on-Tangible-Equity : -178.42% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Goldenwell Biotech's annualized net income for the quarter that ended in Mar. 2024 was $-0.12 Mil. Goldenwell Biotech's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $0.07 Mil. Therefore, Goldenwell Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -178.42%.

The historical rank and industry rank for Goldenwell Biotech's Return-on-Tangible-Equity or its related term are showing as below:

GWLL' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -390.87   Med: -62   Max: -2.41
Current: -102.89

During the past 4 years, Goldenwell Biotech's highest Return-on-Tangible-Equity was -2.41%. The lowest was -390.87%. And the median was -62.00%.

GWLL's Return-on-Tangible-Equity is ranked worse than
96.76% of 1790 companies
in the Consumer Packaged Goods industry
Industry Median: 7.725 vs GWLL: -102.89

Goldenwell Biotech Return-on-Tangible-Equity Historical Data

The historical data trend for Goldenwell Biotech's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech Return-on-Tangible-Equity Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
-2.41 -42.47 -390.87 -81.53

Goldenwell Biotech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.51 -69.90 -113.36 -87.96 -178.42

Competitive Comparison of Goldenwell Biotech's Return-on-Tangible-Equity

For the Packaged Foods subindustry, Goldenwell Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goldenwell Biotech's Return-on-Tangible-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's Return-on-Tangible-Equity falls into.



Goldenwell Biotech Return-on-Tangible-Equity Calculation

Goldenwell Biotech's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-0.117/( (0.202+0.085 )/ 2 )
=-0.117/0.1435
=-81.53 %

Goldenwell Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-0.124/( (0.085+0.054)/ 2 )
=-0.124/0.0695
=-178.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Goldenwell Biotech  (OTCPK:GWLL) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Goldenwell Biotech Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Goldenwell Biotech (Goldenwell Biotech) Business Description

Traded in Other Exchanges
N/A
Address
2071 Midway Drive, Twinsburg, OH, USA, 44087
Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
Executives
Li Yang director, 10 percent owner, officer: Treasurer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie director, officer: Secretary C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu director, 10 percent owner, officer: Chief Executive Officer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines